ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 315 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $1,666,417 | +233.0% | 65,607 | +431.7% | 0.00% | +100.0% |
Q4 2022 | $500,429 | +21.2% | 12,338 | -1.3% | 0.00% | 0.0% |
Q3 2022 | $413,000 | -6.1% | 12,498 | +30.7% | 0.00% | – |
Q1 2022 | $440,000 | -75.5% | 9,561 | -66.7% | 0.00% | -100.0% |
Q3 2021 | $1,795,000 | -22.1% | 28,754 | -17.3% | 0.00% | -33.3% |
Q1 2021 | $2,305,000 | +19.3% | 34,758 | +38.0% | 0.00% | 0.0% |
Q4 2020 | $1,932,000 | -33.9% | 25,182 | -62.9% | 0.00% | -40.0% |
Q3 2020 | $2,923,000 | -12.0% | 67,874 | -11.8% | 0.01% | -16.7% |
Q2 2020 | $3,323,000 | +31.6% | 76,933 | -12.3% | 0.01% | 0.0% |
Q1 2020 | $2,525,000 | -80.3% | 87,766 | -56.6% | 0.01% | -72.7% |
Q4 2019 | $12,841,000 | +221.8% | 202,442 | +43.0% | 0.02% | +175.0% |
Q3 2019 | $3,990,000 | -13.2% | 141,586 | -18.4% | 0.01% | -11.1% |
Q2 2019 | $4,595,000 | +741.6% | 173,413 | +482.3% | 0.01% | +800.0% |
Q1 2019 | $546,000 | -75.4% | 29,781 | -83.3% | 0.00% | -80.0% |
Q4 2018 | $2,220,000 | – | 178,720 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |